Evaxion Biotech A/S expected to post a loss of $3.88 a share - Earnings Preview

Evaxion A/S

21/03/2025 12:39

Evaxion Biotech A/S EVAX.OQ EVAX.O is expected to show a rise in quarterly revenue when it reports  results on March 25 (estimated) for the period ending December 31 2024

The Copenhagen Denmark-based   company is expected to report revenue of $1.66 million, according to the mean estimate from 2 analysts, based on LSEG data.

​LSEG's mean analyst estimate for Evaxion Biotech A/S is for a loss of $3.88 per share.

The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 2 "strong buy" or "buy," no "hold" and no "sell" or "strong sell."

The mean earnings estimate of analysts was unchanged in the last three months. ​

Wall Street's median 12-month price target for Evaxion Biotech A/S is $44.88​, above​ its last closing price of $1.90. ​​​

This summary was machine generated March 21 at 12:39 GMT.  All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)